Currently, vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR)-directed therapies represent the standard of care for metastatic ccRCC, while the molecular sub-classifications of ccRCC remain to be fully elucidated (4). The gene discussed is MTOR; the disease is nonpapillary renal cell carcinoma.